ClinicalTrials.gg
CompletedNCT03006926Updated Dec 13, 2023Results posted

A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma

A Phase 1 interventional study of lenvatinib and pembrolizumab (200 mg) in Hepatocellular Carcinoma, sponsored by Eisai Co., Ltd.. Completed at 26 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-13.

Sponsored by Eisai Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
104
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 121 studies testing lenvatinib in Carcinoma, Hepatocellular — 57 open to participants now, 65 under way, 7 of them phase 3. lenvatinib · Carcinoma, Hepatocellular.

Enrollment
25th of 121
104 · median 48
Started
2017
the only one that year
Phase 1
9 of 121
4 open now
Registered
4th of 121
by date
Lead sponsor
4 of 121
Eisai Co., Ltd.

Among the 121 studies testing lenvatinib in Carcinoma, Hepatocellular, this one is the 25th largest by enrollment, is the only one that started in 2017, is one of 9 in phase 1, and was the 4th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

57 of the 121 studies testing lenvatinib in Carcinoma, Hepatocellular are open now, in 6 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies testing lenvatinib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

This is an open-label Phase 1b study designed to evaluate the tolerability and safety of lenvatinib in combination with pembrolizumab in participants with hepatocellular carcinoma (HCC). The study will evaluate objective response rate and duration of response by modified Response Evaluation Criteria In Solid Tumors (mRECIST) for HCC and Response Evaluation Criteria In Solid Tumors (RECIST 1.1) based on independent imaging review (IIR).

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • hepatocellular carcinoma
  • E7080
  • lenvatinib
  • pembrolizumab
  • Japan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of hepatocellular carcinoma (HCC)
  • HCC for which no other appropriate therapy is available. Note: Expansion Part: No prior systemic therapy for advanced/unresectable HCC
  • Stage B (not applicable for transarterial chemoembolization [TACE]), or stage C based on Barcelona Clinic Liver Cancer (BCLC) staging system
  • At least 1 measurable target lesion according to modified ()
  • score A
  • (ECOG) Performance Status (PS) of 0 to 1
  • Total triiodothyronine (T3) or free T3 and free thyroxine (T4) are within normal limits. (control by thyroid replacement therapy is acceptable.) Participants with T3, free T3 or free T4 abnormalities at screening who are asymptomatic can be eligible
  • Adequately controlled blood pressure
  • Adequate renal function
  • Adequate bone marrow function
  • Adequate blood coagulation function
  • Adequate liver function
  • Males or females age ≥ 18 years at the time of
  • Voluntary agreement to provide written informed consent and the willingness and ability to comply with all aspects of the protocol

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with lenvatinib or any , anti-PD-L1, or anti-PD-L2 agent
  • Active (except for HCC or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the past 36 months
  • Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial
  • Active infection (any infection requiring systemic treatment). or C [HBV/] is allowed
  • Participants with are not eligible, unless they have completed local therapy (eg, whole brain radiation therapy [WBRT], surgery or radiosurgery) and have discontinued the use of for this indication for at least 4 weeks before starting treatment in this study. Any signs (eg, radiologic) or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    lenvatinib 8 or 12 mg plus pembrolizumab 200 mg

    Participants will receive oral lenvatinib at a starting dose of 8 or 12 milligrams (mg) once a day (QD) in combination with intravenous pembrolizumab 200 mg every 3 weeks (Q3W) on a 21-day treatment cycle. The starting dose of lenvatinib will be based on Baseline body weight. Participants weighing greater than or equal to 60 kilograms (kg) will receive 12 mg QD; participants weighing less than 60 kg will receive 8 mg QD.

    Drug: lenvatinib · Drug: pembrolizumab (200 mg)

Interventions

06

What researchers measure

Primary outcomes

  1. DLT Part: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    A TEAE was defined as an adverse event (AE) that emerged during the time from the first dose of study drug to 120 days (if participant initiated new anticancer therapy) following last dose of study drug, was absent at pretreatment (Baseline) or reemerged during treatment, was at pretreatment (Baseline) but stopped before treatment or worsened in severity during treatment relative to the pretreatment state, when AE was continuous. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening (that is, participant was at immediate risk of death from AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug).

    Time frame: From first dose until 120 days after the last dose (up to 50.2 months)

  2. Expansion Part: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    A TEAE was defined as an AE that emerged during the time from the first dose of study drug to 120 days (if participant initiated new anticancer therapy) following last dose of study drug, was absent at pretreatment (Baseline) or reemerged during treatment, was at pretreatment (Baseline) but stopped before treatment or worsened in severity during treatment relative to the pretreatment state, when AE was continuous. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening (that is, participant was at immediate risk of death from AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug).

    Time frame: From first dose until 120 days after the last dose (up to 50.2 months)

  3. DLT Part: Number of Participants With Dose Limiting Toxicities (DLTs)

    DLT was graded according to Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03). DLT was defined as any of the following: (1) any of the hematological or nonhematological toxicities considered to be at least possibly related to lenvatinib and/or pembrolizumab occurring during Cycle 1; (2) failure to administer \>=75 percent (%) of the planned dosage of lenvatinib as a result of treatment-related toxicity during Cycle 1; (3) participants who discontinued treatment due to treatment-related toxicity in Cycle 1; (4) greater than (\>) 2 week delay in starting pembrolizumab in Cycle 2 because of a treatment-related toxicity, even if the toxicity did not meet DLT criteria.

    Time frame: From first dose of study drug up to Cycle 1 Day 21 (Cycle length= 21 days)

  4. DLT+Expansion Part: Objective Response Rate (ORR) Based on mRECIST and RECIST Version (v) 1.1 Assessed by Independent Imaging Review (IIR)

    ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) and Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 assessed by IIR analysis. Responses (PR or CR) were confirmed no less than 4 weeks after the initial response. CR defined as disappearance of all target lesions and non-target lesions (a short diameter is \<10 millimeter \[mm\] if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the long diameter (LD) (hereafter referred to as sum of LD) of all target lesions, as compared with Baseline summed LD.

    Time frame: From the first dose of study drug to the first date of documentation of PD or death, whichever occurred first (up to 46.2 months)

  5. DLT+Expansion Part: Duration of Response (DOR) Based on mRECIST Assessed by IIR

    DOR was defined as the time from the first documentation of CR or PR to the date of first documentation of PD or death (whichever occurred first) in participants with confirmed CR or PR based on mRECIST assessed by IIR analysis. CR defined as disappearance of all target lesions and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD. PD was defined as at least a 20% increase in the sum of LD of target and non-target lesions as compared with the smallest sum of LD, and the increase of LD was at least 5 mm (including new lesions).

    Time frame: From date of first documented confirmed CR or PR until date of first documentation of PD or death, whichever occurred first (up to 46.2 months)

  6. DLT+Expansion Part: Duration of Response (DOR) Based on RECIST v1.1 Assessed by IIR

    DOR was defined as the time from the first documentation of CR or PR to the date of first documentation of PD or death (whichever occurred first) in participants with confirmed CR or PR based on RECIST v1.1 assessed by IIR analysis. CR defined as disappearance of all target lesions and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD. PD was defined as at least a 20% increase in the sum of LD of target and non-target lesions as compared with the smallest sum of LD, and the increase of LD was at least 5 mm (including new lesions).

    Time frame: From date of first documented confirmed CR or PR until date of first documentation of PD or death, whichever occurred first (up to 46.2 months)

Secondary outcomes

  1. DLT+Expansion Part: Objective Response Rate (ORR) Based on mRECIST Assessed by Investigator Review

    ORR was defined as the percentage of participants who had BOR of CR or PR based on mRECIST assessed by investigator review. Responses (PR or CR) were confirmed no less than 4 weeks after the initial response. CR defined as disappearance of all target lesions and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD.

    Time frame: From the first dose of study drug to the first date of documentation of PD or death, whichever occurred first (up to 46.2 months)

  2. DLT+Expansion Part: Duration of Response (DOR) Based on mRECIST Assessed by Investigator Review

    DOR was defined as the time from the first documentation of CR or PR to the date of first documentation of PD or death (whichever occurred first) based on mRECIST assessed by investigator review. CR defined as disappearance of all target and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD. PD was defined as at least a 20% increase in the sum of LD of target and non-target lesions as compared with the smallest sum of LD, and the increase of LD was at least 5 mm (including new lesions).

    Time frame: From date of first documented confirmed CR or PR until date of first documentation of PD or death, whichever occurred first (up to 46.2 months)

  3. DLT+Expansion Part: Progression-free Survival (PFS) Based on mRECIST and RECIST v1.1 Assessed by IIR and Based on mRECIST Assessed by Investigator Review

    PFS was defined as the time from the first study dose date to the date of first documentation of PD or death (whichever occurred first) based on mRECIST and RECIST v1.1 assessed by IIR, and mRECIST assessed by investigator review. PD was defined as at least a 20% increase in the sum of LD of target and non-target lesions as compared with the smallest sum of LD, and the increase of LD was at least 5 mm (including new lesions).

    Time frame: From the first study dose date to the date of first documentation of PD or death, whichever occurred first (up to 46.2 months)

  4. DLT+Expansion Part: Time-to-Progression (TTP) Based on mRECIST and RECIST v1.1 Assessed by IIR and Based on mRECIST Assessed by Investigator Review

    TTP was defined as the time from the first study dose date to the date of first documentation of PD, based on mRECIST and RECIST v1.1 assessed by IIR and mRECIST assessed by an investigator review. PD was defined as at least a 20% increase in the sum of LD of target and non-target lesions as compared with the smallest sum of LD, and the increase of LD was at least 5 mm (including new lesions).

    Time frame: From date of first dose of study drug until PD (up to 46.2 months)

  5. DLT+Expansion Part: Time-to-Response (TTR) Based on mRECIST Assessed by IIR

    TTR was defined as the time from the date of first study dose to the date of first documentation of CR or PR, in participants with confirmed CR or PR. It was evaluated according to mRECIST assessed by IIR. CR defined as disappearance of all target and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD.

    Time frame: From date of first dose of study drug until CR or PR (up to 46.2 months)

  6. DLT+Expansion Part: Time-to-Response (TTR) Based on RECIST v1.1 Assessed by IIR

    TTR was defined as the time from the date of first study dose to the date of first documentation of CR or PR, in participants with confirmed CR or PR. It was evaluated according to RECIST v1.1 assessed by IIR. CR defined as disappearance of all target and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD.

    Time frame: From date of first dose of study drug until CR or PR (up to 46.2 months)

  7. DLT+Expansion Part: Time-to-Response (TTR) Based on mRECIST Assessed by Investigator Review

    TTR was defined as the time from the date of first study dose to the date of first documentation of CR or PR, in participants with confirmed CR or PR. It was evaluated according to mRECIST assessed by investigator review. CR defined as disappearance of all target and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD.

    Time frame: From date of first dose of study drug until CR or PR (up to 46.2 months)

  8. DLT+Expansion Part: Overall Survival (OS)

    OS was measured from the date of first dose of study drug until date of death from any cause. Participants who were lost to follow-up or who were alive at the date of data cutoff were censored at the date the participants were last known alive, whichever came earlier.

    Time frame: From the date of first dose of study drug until date of death from any cause (up to 48.1 months)

  9. DLT+Expansion Part, Cmax: Maximum Observed Plasma Concentration for Lenvatinib

    Cmax was defined as the maximum plasma concentration for lenvatinib. Cmax was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by liquid chromatography with tandem mass spectrometry (LC-MS/MS). As per pharmacokinetic (PK) planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

    Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=21 days)

  10. DLT+Expansion Part, Tmax: Time to Reach the Cmax for Lenvatinib

    Tmax was defined as the time to reach maximum observed plasma concentration (Cmax) for lenvatinib. Tmax was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

    Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=21 days)

  11. DLT+Expansion Part, AUC(0-t): Area Under the Plasma Concentration-time Curve From Zero Time to the Last Measurable Point for Lenvatinib

    AUC(0-t) was defined as the area under the plasma concentration-time curve from 0 time to last measurable point for lenvatinib. AUC(0-t) was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

    Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=21 days)

  12. DLT+Expansion Part, AUC(0-ti): Area Under The Plasma Concentration-time Curve From Zero (Pre-Dose) to a Given Sampling Time (ti) for Lenvatinib

    AUC(0-ti) was defined as the area under the plasma concentration-time curve from 0 to a given sampling time for lenvatinib. AUC(0-ti) was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

    Time frame: Cycle 1 Days 1 and 15: 0-8 hours post-dose (Cycle length=21 days)

  13. DLT+Expansion Part, AUC(0-Inf): Area Under the Plasma Concentration-time Curve From Zero to Infinity for Lenvatinib

    AUC(0-Inf) was defined as the area under the plasma concentration-time curve from 0 to infinity for lenvatinib. AUC(0-Inf) was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

    Time frame: Cycle 1 Days 1 and 15: 0-24 hours post-dose (Cycle length=21 days)

  14. DLT+Expansion Part, t1/2: Terminal Elimination Phase Half-Life for Lenvatinib

    t1/2 was defined as the terminal elimination phase half-life for lenvatinib. t1/2 was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

    Time frame: Cycle 1 Days 1 and 15: 0-24 hours post-dose (Cycle length=21 days)

  15. DLT+Expansion Part, CL/F: Apparent Total Clearance for Lenvatinib

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as (Dose/AUC(0-inf))/F. Where AUC(0-inf) is the area under the plasma concentration-time curve from zero to infinity and F is the bioavailability of the drug. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

    Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)

  16. DLT+Expansion Part, Vz/F: Apparent Terminal Volume of Distribution for Lenvatinib

    Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F was calculated as (CL/F)/Lambda Z. Where, CL/F is the apparent total clearance and lambda Z is the apparent terminal elimination rate constant. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

    Time frame: Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=21 days)

  17. DLT+Expansion Part, Css,Max: Maximum Observed Plasma Concentration at Steady State for Lenvatinib

    Css,max was defined as the maximum plasma concentration at steady state for lenvatinib. Css,max was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

    Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)

  18. DLT+Expansion Part, Css,Min: Minimum Observed Plasma Concentration at Steady State for Lenvatinib

    Css,min is the minimum plasma concentration at steady state for lenvatinib. Css,min was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

    Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)

  19. DLT+Expansion Part, Tss,Max: Time to Maximum Observed Concentration at Steady State For Lenvatinib

    Tss,Max was defined as the time to reach maximum observed plasma concentration of lenvatinib at steady state. Tss,Max was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

    Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)

  20. DLT+Expansion Part, AUC(0-tau): Area Under the Plasma Concentration-time Curve Over the Dosing Interval for Lenvatinib

    AUC(0-tau) was defined as the area under the plasma concentration-time curve over dosing interval for lenvatinib. AUC(0-tau) was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

    Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)

  21. DLT+Expansion Part, Clss/F: Apparent Total Clearance Following Oral Administration at Steady State for Lenvatinib

    Clearance of a drug at steady state is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CLss/F was calculated as (Dose/AUC(0-tau))/F. Where, AUC(0-tau) is the area under the plasma concentration-time curve over the dosing interval and F is the bioavailability of the drug. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

    Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)

  22. DLT+Expansion Part, Css,Av: Average Steady State Plasma Concentration for Lenvatinib

    Css,Av was defined as the average plasma concentration at steady state for lenvatinib. Css,Av was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. Css,Av was calculated as AUC(0-tau)/tau. Where, AUC(0-tau) is the area under the plasma concentration-time curve over the dosing interval and tau is the length of dosing interval. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

    Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)

  23. DLT+Expansion Part, Vz,ss/F: Apparent Terminal Volume of Distribution at Steady State for Lenvatinib

    Volume of distribution at steady state was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz,ss/F was calculated as (CLss/F)/Lambda Z. Where, CLss/F is the apparent total clearance following oral administration at steady state and lambda Z is the apparent terminal elimination rate constant. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

    Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)

  24. DLT+Expansion Part, Rac (Cmax): Accumulation Ratio of Cmax for Lenvatinib

    Rac(Cmax) was calculated as Css,max at Cycle 1 Day 15/Cmax at Cycle 1 Day 1. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

    Time frame: Cycle 1 Days 1 and 15: 0-24 hours post-dose (Cycle length=21 days)

  25. DLT+Expansion Part, Rac (AUC0-8 Hour): Accumulation Ratio of AUC(0-8 Hour) for Lenvatinib

    Rac(AUC0-8 hour) was calculated as AUC(0-8 hour) at Cycle 1 Day 15/AUC(0-8 hour) at Cycle 1 Day 1. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

    Time frame: Cycle 1 Days 1 and 15: 0-8 hours post-dose (Cycle length=21 days)

  26. DLT+Expansion Part, %PTF: Percent (%) Peak-trough Fluctuation for Lenvatinib

    The PTF within complete dosing interval at steady state, calculated as PTF (%) = (\[Css,max - Css,min\]/Css,Av)\* 100. Where, Css,max is the maximum observed plasma concentration at steady state and Css,min is the minimum observed plasma concentration at steady state and Css,Av average steady state plasma concentration. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

    Time frame: Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)

  27. DLT+Expansion Part, Ctrough: Trough (Pre-dose) Serum Concentration for Pembrolizumab

    Ctrough was defined as trough (pre-dose) serum concentration for pembrolizumab at steady state.

    Time frame: Cycles 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36: Pre-dose (each Cycle length=21 days)

  28. DLT+Expansion Part: Number of Participants Positive for Serum Anti-drug Antibodies (ADA) Status

    ADA positive was defined as participants with at least one pre-treatment or post-dose sample positive in the confirmatory assay for antibodies against pembrolizumab. ADA was assessed using a validated electrochemiluminescence (ECL) immunoassay.

    Time frame: Cycles 1 and 6 Day 1: Pre-dose (each cycle length=21 days)

07

Results

Posted Dec 31, 2020

Participant flow

Participants took part in the study at 24 investigative sites in the United States, Japan, United Kingdom, France, Italy, Spain, and Russian Federation from 13 February 2017 to 22 November 2022.

Participant flow — Overall Study
MilestoneDLT Part: Lenvatinib 12 mg or 8 mg + Pembrolizumab 200 mgExpansion Part: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg
Started698
Japanese population616
Non-japanese population082
Completed60
Not completed098
Withdrew: Adverse event027
Withdrew: Withdrawal by subject01
Withdrew: Radiological disease progression052
Withdrew: Clinical disease progression010
Withdrew: Other08

Outcome measures

PrimaryDLT Part: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

A TEAE was defined as an adverse event (AE) that emerged during the time from the first dose of study drug to 120 days (if participant initiated new anticancer therapy) following last dose of study drug, was absent at pretreatment (Baseline) or reemerged during treatment, was at pretreatment (Baseline) but stopped before treatment or worsened in severity during treatment relative to the pretreatment state, when AE was continuous. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening (that is, participant was at immediate risk of death from AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug).

Time frame:
From first dose until 120 days after the last dose (up to 50.2 months)
Reported as:
Count of participants · Participants
DLT Part: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsDLT Part: Lenvatinib 12 mg or 8 mg + Pembrolizumab 200 mg
TEAEs6
SAEs4
PrimaryExpansion Part: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

A TEAE was defined as an AE that emerged during the time from the first dose of study drug to 120 days (if participant initiated new anticancer therapy) following last dose of study drug, was absent at pretreatment (Baseline) or reemerged during treatment, was at pretreatment (Baseline) but stopped before treatment or worsened in severity during treatment relative to the pretreatment state, when AE was continuous. An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening (that is, participant was at immediate risk of death from AE as it occurred; this did not include an event that, had it occurred in a more severe form or was allowed to continue, might have caused death), required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect (in the child of a participant who was exposed to the study drug).

Time frame:
From first dose until 120 days after the last dose (up to 50.2 months)
Reported as:
Count of participants · Participants
Expansion Part: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsExpansion Part: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg
TEAEs97
SAEs73
PrimaryDLT Part: Number of Participants With Dose Limiting Toxicities (DLTs)

DLT was graded according to Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03). DLT was defined as any of the following: (1) any of the hematological or nonhematological toxicities considered to be at least possibly related to lenvatinib and/or pembrolizumab occurring during Cycle 1; (2) failure to administer \>=75 percent (%) of the planned dosage of lenvatinib as a result of treatment-related toxicity during Cycle 1; (3) participants who discontinued treatment due to treatment-related toxicity in Cycle 1; (4) greater than (\>) 2 week delay in starting pembrolizumab in Cycle 2 because of a treatment-related toxicity, even if the toxicity did not meet DLT criteria.

Time frame:
From first dose of study drug up to Cycle 1 Day 21 (Cycle length= 21 days)
Reported as:
Count of participants · Participants
DLT Part: Number of Participants With Dose Limiting Toxicities (DLTs)
ParticipantsDLT Part: Lenvatinib 12 mg or 8 mg + Pembrolizumab 200 mg
DLT Part: Number of Participants With Dose Limiting Toxicities (DLTs)0
PrimaryDLT+Expansion Part: Objective Response Rate (ORR) Based on mRECIST and RECIST Version (v) 1.1 Assessed by Independent Imaging Review (IIR)

ORR was defined as the percentage of participants who had best overall response (BOR) of complete response (CR) or partial response (PR) based on modified Response Evaluation Criteria in Solid Tumors (mRECIST) and Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 assessed by IIR analysis. Responses (PR or CR) were confirmed no less than 4 weeks after the initial response. CR defined as disappearance of all target lesions and non-target lesions (a short diameter is \<10 millimeter \[mm\] if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the long diameter (LD) (hereafter referred to as sum of LD) of all target lesions, as compared with Baseline summed LD.

Time frame:
From the first dose of study drug to the first date of documentation of PD or death, whichever occurred first (up to 46.2 months)
Reported as:
Number · percentage of participants
DLT+Expansion Part: Objective Response Rate (ORR) Based on mRECIST and RECIST Version (v) 1.1 Assessed by Independent Imaging Review (IIR)
percentage of participantsHCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg
RECIST v1.138.0 (28.5 to 48.3)
mRECIST46.0 (36.0 to 56.3)
PrimaryDLT+Expansion Part: Duration of Response (DOR) Based on mRECIST Assessed by IIR

DOR was defined as the time from the first documentation of CR or PR to the date of first documentation of PD or death (whichever occurred first) in participants with confirmed CR or PR based on mRECIST assessed by IIR analysis. CR defined as disappearance of all target lesions and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD. PD was defined as at least a 20% increase in the sum of LD of target and non-target lesions as compared with the smallest sum of LD, and the increase of LD was at least 5 mm (including new lesions).

Time frame:
From date of first documented confirmed CR or PR until date of first documentation of PD or death, whichever occurred first (up to 46.2 months)
Reported as:
Median · months
DLT+Expansion Part: Duration of Response (DOR) Based on mRECIST Assessed by IIR
monthsHCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg
DLT+Expansion Part: Duration of Response (DOR) Based on mRECIST Assessed by IIR16.7 (8.6 to NA)
PrimaryDLT+Expansion Part: Duration of Response (DOR) Based on RECIST v1.1 Assessed by IIR

DOR was defined as the time from the first documentation of CR or PR to the date of first documentation of PD or death (whichever occurred first) in participants with confirmed CR or PR based on RECIST v1.1 assessed by IIR analysis. CR defined as disappearance of all target lesions and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD. PD was defined as at least a 20% increase in the sum of LD of target and non-target lesions as compared with the smallest sum of LD, and the increase of LD was at least 5 mm (including new lesions).

Time frame:
From date of first documented confirmed CR or PR until date of first documentation of PD or death, whichever occurred first (up to 46.2 months)
Reported as:
Median · months
DLT+Expansion Part: Duration of Response (DOR) Based on RECIST v1.1 Assessed by IIR
monthsHCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg
DLT+Expansion Part: Duration of Response (DOR) Based on RECIST v1.1 Assessed by IIRNA (12.6 to NA)
SecondaryDLT+Expansion Part: Objective Response Rate (ORR) Based on mRECIST Assessed by Investigator Review

ORR was defined as the percentage of participants who had BOR of CR or PR based on mRECIST assessed by investigator review. Responses (PR or CR) were confirmed no less than 4 weeks after the initial response. CR defined as disappearance of all target lesions and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD.

Time frame:
From the first dose of study drug to the first date of documentation of PD or death, whichever occurred first (up to 46.2 months)
Reported as:
Number · percentage of participants
DLT+Expansion Part: Objective Response Rate (ORR) Based on mRECIST Assessed by Investigator Review
percentage of participantsHCC 1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg
DLT+Expansion Part: Objective Response Rate (ORR) Based on mRECIST Assessed by Investigator Review43.0 (33.1 to 53.3)
SecondaryDLT+Expansion Part: Duration of Response (DOR) Based on mRECIST Assessed by Investigator Review

DOR was defined as the time from the first documentation of CR or PR to the date of first documentation of PD or death (whichever occurred first) based on mRECIST assessed by investigator review. CR defined as disappearance of all target and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD. PD was defined as at least a 20% increase in the sum of LD of target and non-target lesions as compared with the smallest sum of LD, and the increase of LD was at least 5 mm (including new lesions).

Time frame:
From date of first documented confirmed CR or PR until date of first documentation of PD or death, whichever occurred first (up to 46.2 months)
Reported as:
Median · months
DLT+Expansion Part: Duration of Response (DOR) Based on mRECIST Assessed by Investigator Review
monthsHCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg
DLT+Expansion Part: Duration of Response (DOR) Based on mRECIST Assessed by Investigator Review17.1 (6.9 to 19.3)
SecondaryDLT+Expansion Part: Progression-free Survival (PFS) Based on mRECIST and RECIST v1.1 Assessed by IIR and Based on mRECIST Assessed by Investigator Review

PFS was defined as the time from the first study dose date to the date of first documentation of PD or death (whichever occurred first) based on mRECIST and RECIST v1.1 assessed by IIR, and mRECIST assessed by investigator review. PD was defined as at least a 20% increase in the sum of LD of target and non-target lesions as compared with the smallest sum of LD, and the increase of LD was at least 5 mm (including new lesions).

Time frame:
From the first study dose date to the date of first documentation of PD or death, whichever occurred first (up to 46.2 months)
Reported as:
Median · months
DLT+Expansion Part: Progression-free Survival (PFS) Based on mRECIST and RECIST v1.1 Assessed by IIR and Based on mRECIST Assessed by Investigator Review
monthsHCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg
mRECIST: IIR9.6 (5.6 to 11.8)
RECIST v1.1: IIR9.6 (7.6 to 10.8)
mRECIST: Investigator Review9.3 (7.4 to 9.8)
SecondaryDLT+Expansion Part: Time-to-Progression (TTP) Based on mRECIST and RECIST v1.1 Assessed by IIR and Based on mRECIST Assessed by Investigator Review

TTP was defined as the time from the first study dose date to the date of first documentation of PD, based on mRECIST and RECIST v1.1 assessed by IIR and mRECIST assessed by an investigator review. PD was defined as at least a 20% increase in the sum of LD of target and non-target lesions as compared with the smallest sum of LD, and the increase of LD was at least 5 mm (including new lesions).

Time frame:
From date of first dose of study drug until PD (up to 46.2 months)
Reported as:
Median · months
DLT+Expansion Part: Time-to-Progression (TTP) Based on mRECIST and RECIST v1.1 Assessed by IIR and Based on mRECIST Assessed by Investigator Review
monthsHCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg
mRECIST: IIR9.9 (9.3 to 20.0)
RECIST v1.1: IIR10.8 (9.6 to 24.3)
mRECIST: Investigator Review9.8 (7.7 to 15.9)
SecondaryDLT+Expansion Part: Time-to-Response (TTR) Based on mRECIST Assessed by IIR

TTR was defined as the time from the date of first study dose to the date of first documentation of CR or PR, in participants with confirmed CR or PR. It was evaluated according to mRECIST assessed by IIR. CR defined as disappearance of all target and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD.

Time frame:
From date of first dose of study drug until CR or PR (up to 46.2 months)
Reported as:
Median · months
DLT+Expansion Part: Time-to-Response (TTR) Based on mRECIST Assessed by IIR
monthsHCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg
DLT+Expansion Part: Time-to-Response (TTR) Based on mRECIST Assessed by IIR2.5 (1.2 to 7.6)
SecondaryDLT+Expansion Part: Time-to-Response (TTR) Based on RECIST v1.1 Assessed by IIR

TTR was defined as the time from the date of first study dose to the date of first documentation of CR or PR, in participants with confirmed CR or PR. It was evaluated according to RECIST v1.1 assessed by IIR. CR defined as disappearance of all target and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD.

Time frame:
From date of first dose of study drug until CR or PR (up to 46.2 months)
Reported as:
Median · months
DLT+Expansion Part: Time-to-Response (TTR) Based on RECIST v1.1 Assessed by IIR
monthsHCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg
DLT+Expansion Part: Time-to-Response (TTR) Based on RECIST v1.1 Assessed by IIR2.8 (1.2 to 13.8)
SecondaryDLT+Expansion Part: Time-to-Response (TTR) Based on mRECIST Assessed by Investigator Review

TTR was defined as the time from the date of first study dose to the date of first documentation of CR or PR, in participants with confirmed CR or PR. It was evaluated according to mRECIST assessed by investigator review. CR defined as disappearance of all target and non-target lesions (a short diameter is \<10 mm if it exists in a lymph node). PR defined as at least 30% decrease in the sum of the LD (hereafter referred to as sum of LD) of all target and non-target lesions, as compared with Baseline summed LD.

Time frame:
From date of first dose of study drug until CR or PR (up to 46.2 months)
Reported as:
Median · months
DLT+Expansion Part: Time-to-Response (TTR) Based on mRECIST Assessed by Investigator Review
monthsHCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg
DLT+Expansion Part: Time-to-Response (TTR) Based on mRECIST Assessed by Investigator Review2.7 (1.2 to 15.7)
SecondaryDLT+Expansion Part: Overall Survival (OS)

OS was measured from the date of first dose of study drug until date of death from any cause. Participants who were lost to follow-up or who were alive at the date of data cutoff were censored at the date the participants were last known alive, whichever came earlier.

Time frame:
From the date of first dose of study drug until date of death from any cause (up to 48.1 months)
Reported as:
Median · months
DLT+Expansion Part: Overall Survival (OS)
monthsHCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg
DLT+Expansion Part: Overall Survival (OS)20.4 (14.4 to 25.9)
SecondaryDLT+Expansion Part, Cmax: Maximum Observed Plasma Concentration for Lenvatinib

Cmax was defined as the maximum plasma concentration for lenvatinib. Cmax was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by liquid chromatography with tandem mass spectrometry (LC-MS/MS). As per pharmacokinetic (PK) planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

Time frame:
Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=21 days)
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
DLT+Expansion Part, Cmax: Maximum Observed Plasma Concentration for Lenvatinib
nanogram per milliliter (ng/mL)DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Japanese Participants: Lenvatinib 12 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg
DLT+Expansion Part, Cmax: Maximum Observed Plasma Concentration for Lenvatinib127 ± 37.798.3 ± NA168 ± 29.7145 ± 30.9
SecondaryDLT+Expansion Part, Tmax: Time to Reach the Cmax for Lenvatinib

Tmax was defined as the time to reach maximum observed plasma concentration (Cmax) for lenvatinib. Tmax was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

Time frame:
Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=21 days)
Reported as:
Median · hours
DLT+Expansion Part, Tmax: Time to Reach the Cmax for Lenvatinib
hoursDLT+Expansion Part, Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Japanese Participants: Lenvatinib 12 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg
DLT+Expansion Part, Tmax: Time to Reach the Cmax for Lenvatinib3.90 (1.00 to 7.97)4.00 (NA to NA)3.92 (0.82 to 7.92)4.00 (2.00 to 8.80)
SecondaryDLT+Expansion Part, AUC(0-t): Area Under the Plasma Concentration-time Curve From Zero Time to the Last Measurable Point for Lenvatinib

AUC(0-t) was defined as the area under the plasma concentration-time curve from 0 time to last measurable point for lenvatinib. AUC(0-t) was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

Time frame:
Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=21 days)
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*h/mL)
DLT+Expansion Part, AUC(0-t): Area Under the Plasma Concentration-time Curve From Zero Time to the Last Measurable Point for Lenvatinib
nanogram*hour per milliliter (ng*h/mL)DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Japanese Participants: Lenvatinib 12 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg
DLT+Expansion Part, AUC(0-t): Area Under the Plasma Concentration-time Curve From Zero Time to the Last Measurable Point for Lenvatinib1230 ± 7.61—1690 ± 23.71950 ± 39.2
SecondaryDLT+Expansion Part, AUC(0-ti): Area Under The Plasma Concentration-time Curve From Zero (Pre-Dose) to a Given Sampling Time (ti) for Lenvatinib

AUC(0-ti) was defined as the area under the plasma concentration-time curve from 0 to a given sampling time for lenvatinib. AUC(0-ti) was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

Time frame:
Cycle 1 Days 1 and 15: 0-8 hours post-dose (Cycle length=21 days)
Reported as:
Geometric mean · ng*h/mL
DLT+Expansion Part, AUC(0-ti): Area Under The Plasma Concentration-time Curve From Zero (Pre-Dose) to a Given Sampling Time (ti) for Lenvatinib
ng*h/mLDLT+Expansion Part, Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Japanese Participants: Lenvatinib 12 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg
Cycle 1 Day 1: 0-8 hours post-dose673 ± 29.3—868 ± 25.9736 ± 42.2
Cycle 1 Day 15: 0-8 hours post-dose793 ± 36.0—1020 ± 57.41120 ± 18.2
SecondaryDLT+Expansion Part, AUC(0-Inf): Area Under the Plasma Concentration-time Curve From Zero to Infinity for Lenvatinib

AUC(0-Inf) was defined as the area under the plasma concentration-time curve from 0 to infinity for lenvatinib. AUC(0-Inf) was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

Time frame:
Cycle 1 Days 1 and 15: 0-24 hours post-dose (Cycle length=21 days)
Reported as:
Geometric mean · ng*h/mL
DLT+Expansion Part, AUC(0-Inf): Area Under the Plasma Concentration-time Curve From Zero to Infinity for Lenvatinib
ng*h/mLDLT+Expansion Part, Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Japanese Participants: Lenvatinib 12 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg
Cycle 1 Day 1: 0-24 hours post-dose1340 ± NA—1900 ± 31.81540 ± 16.6
Cycle 1 Day 15: 0-24 hours post-dose——4690 ± NA2530 ± NA
SecondaryDLT+Expansion Part, t1/2: Terminal Elimination Phase Half-Life for Lenvatinib

t1/2 was defined as the terminal elimination phase half-life for lenvatinib. t1/2 was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

Time frame:
Cycle 1 Days 1 and 15: 0-24 hours post-dose (Cycle length=21 days)
Reported as:
Geometric mean · hours
DLT+Expansion Part, t1/2: Terminal Elimination Phase Half-Life for Lenvatinib
hoursDLT+Expansion Part, Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Japanese Participants: Lenvatinib 12 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg
Cycle 1 Day 1: 0-24 hours post-dose7.71 ± NA—6.64 ± 16.05.75 ± 3.07
Cycle 1 Day 15: 0-24 hours post-dose——7.33 ± NA6.48 ± NA
SecondaryDLT+Expansion Part, CL/F: Apparent Total Clearance for Lenvatinib

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F was calculated as (Dose/AUC(0-inf))/F. Where AUC(0-inf) is the area under the plasma concentration-time curve from zero to infinity and F is the bioavailability of the drug. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

Time frame:
Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)
Reported as:
Geometric mean · liter per hour (L/h)
DLT+Expansion Part, CL/F: Apparent Total Clearance for Lenvatinib
liter per hour (L/h)DLT+Expansion Part, Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Japanese Participants: Lenvatinib 12 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg
DLT+Expansion Part, CL/F: Apparent Total Clearance for Lenvatinib5.98 ± NA—6.32 ± 31.67.79 ± 16.7
SecondaryDLT+Expansion Part, Vz/F: Apparent Terminal Volume of Distribution for Lenvatinib

Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz/F was calculated as (CL/F)/Lambda Z. Where, CL/F is the apparent total clearance and lambda Z is the apparent terminal elimination rate constant. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

Time frame:
Cycle 1 Day 1: 0-24 hours post-dose (Cycle length=21 days)
Reported as:
Geometric mean · liter
DLT+Expansion Part, Vz/F: Apparent Terminal Volume of Distribution for Lenvatinib
literDLT+Expansion Part, Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Japanese Participants: Lenvatinib 12 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg
DLT+Expansion Part, Vz/F: Apparent Terminal Volume of Distribution for Lenvatinib66.6 ± NA—60.6 ± 23.264.7 ± 19.8
SecondaryDLT+Expansion Part, Css,Max: Maximum Observed Plasma Concentration at Steady State for Lenvatinib

Css,max was defined as the maximum plasma concentration at steady state for lenvatinib. Css,max was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

Time frame:
Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)
Reported as:
Geometric mean · ng/mL
DLT+Expansion Part, Css,Max: Maximum Observed Plasma Concentration at Steady State for Lenvatinib
ng/mLDLT+Expansion Part, Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Japanese Participants: Lenvatinib 12 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg
DLT+Expansion Part, Css,Max: Maximum Observed Plasma Concentration at Steady State for Lenvatinib154 ± 25.1145 ± NA201 ± 53.5193 ± 17.8
SecondaryDLT+Expansion Part, Css,Min: Minimum Observed Plasma Concentration at Steady State for Lenvatinib

Css,min is the minimum plasma concentration at steady state for lenvatinib. Css,min was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

Time frame:
Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)
Reported as:
Geometric mean · ng/mL
DLT+Expansion Part, Css,Min: Minimum Observed Plasma Concentration at Steady State for Lenvatinib
ng/mLDLT+Expansion Part, Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Japanese Participants: Lenvatinib 12 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg
DLT+Expansion Part, Css,Min: Minimum Observed Plasma Concentration at Steady State for Lenvatinib42.9 ± 24.714.3 ± NA33.4 ± 48.134.3 ± 51.3
SecondaryDLT+Expansion Part, Tss,Max: Time to Maximum Observed Concentration at Steady State For Lenvatinib

Tss,Max was defined as the time to reach maximum observed plasma concentration of lenvatinib at steady state. Tss,Max was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

Time frame:
Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)
Reported as:
Median · hours
DLT+Expansion Part, Tss,Max: Time to Maximum Observed Concentration at Steady State For Lenvatinib
hoursDLT+Expansion Part, Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Japanese Participants: Lenvatinib 12 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg
DLT+Expansion Part, Tss,Max: Time to Maximum Observed Concentration at Steady State For Lenvatinib6.01 (4.00 to 8.00)4.02 (NA to NA)3.89 (2.02 to 7.77)4.00 (1.98 to 4.42)
SecondaryDLT+Expansion Part, AUC(0-tau): Area Under the Plasma Concentration-time Curve Over the Dosing Interval for Lenvatinib

AUC(0-tau) was defined as the area under the plasma concentration-time curve over dosing interval for lenvatinib. AUC(0-tau) was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

Time frame:
Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)
Reported as:
Geometric mean · ng*h/mL
DLT+Expansion Part, AUC(0-tau): Area Under the Plasma Concentration-time Curve Over the Dosing Interval for Lenvatinib
ng*h/mLDLT+Expansion Part, Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Japanese Participants: Lenvatinib 12 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg
DLT+Expansion Part, AUC(0-tau): Area Under the Plasma Concentration-time Curve Over the Dosing Interval for Lenvatinib——4150 ± NA2330 ± 16.5
SecondaryDLT+Expansion Part, Clss/F: Apparent Total Clearance Following Oral Administration at Steady State for Lenvatinib

Clearance of a drug at steady state is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CLss/F was calculated as (Dose/AUC(0-tau))/F. Where, AUC(0-tau) is the area under the plasma concentration-time curve over the dosing interval and F is the bioavailability of the drug. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

Time frame:
Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)
Reported as:
Geometric mean · L/h
DLT+Expansion Part, Clss/F: Apparent Total Clearance Following Oral Administration at Steady State for Lenvatinib
L/hDLT+Expansion Part, Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Japanese Participants: Lenvatinib 12 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg
DLT+Expansion Part, Clss/F: Apparent Total Clearance Following Oral Administration at Steady State for Lenvatinib——2.89 ± NA5.14 ± 16.4
SecondaryDLT+Expansion Part, Css,Av: Average Steady State Plasma Concentration for Lenvatinib

Css,Av was defined as the average plasma concentration at steady state for lenvatinib. Css,Av was derived by non-compartmental analysis using lenvatinib plasma concentrations quantified by LC-MS/MS. Css,Av was calculated as AUC(0-tau)/tau. Where, AUC(0-tau) is the area under the plasma concentration-time curve over the dosing interval and tau is the length of dosing interval. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

Time frame:
Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)
Reported as:
Geometric mean · ng/mL
DLT+Expansion Part, Css,Av: Average Steady State Plasma Concentration for Lenvatinib
ng/mLDLT+Expansion Part, Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Japanese Participants: Lenvatinib 12 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg
DLT+Expansion Part, Css,Av: Average Steady State Plasma Concentration for Lenvatinib——173 ± NA97.2 ± 16.4
SecondaryDLT+Expansion Part, Vz,ss/F: Apparent Terminal Volume of Distribution at Steady State for Lenvatinib

Volume of distribution at steady state was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vz,ss/F was calculated as (CLss/F)/Lambda Z. Where, CLss/F is the apparent total clearance following oral administration at steady state and lambda Z is the apparent terminal elimination rate constant. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

Time frame:
Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)
Reported as:
Geometric mean · liter
DLT+Expansion Part, Vz,ss/F: Apparent Terminal Volume of Distribution at Steady State for Lenvatinib
literDLT+Expansion Part, Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Japanese Participants: Lenvatinib 12 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg
DLT+Expansion Part, Vz,ss/F: Apparent Terminal Volume of Distribution at Steady State for Lenvatinib——30.6 ± NA48.5 ± NA
SecondaryDLT+Expansion Part, Rac (Cmax): Accumulation Ratio of Cmax for Lenvatinib

Rac(Cmax) was calculated as Css,max at Cycle 1 Day 15/Cmax at Cycle 1 Day 1. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

Time frame:
Cycle 1 Days 1 and 15: 0-24 hours post-dose (Cycle length=21 days)
Reported as:
Geometric mean · ratio
DLT+Expansion Part, Rac (Cmax): Accumulation Ratio of Cmax for Lenvatinib
ratioDLT+Expansion Part, Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Japanese Participants: Lenvatinib 12 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg
DLT+Expansion Part, Rac (Cmax): Accumulation Ratio of Cmax for Lenvatinib1.07 ± 28.61.48 ± NA1.17 ± 33.91.38 ± 41.7
SecondaryDLT+Expansion Part, Rac (AUC0-8 Hour): Accumulation Ratio of AUC(0-8 Hour) for Lenvatinib

Rac(AUC0-8 hour) was calculated as AUC(0-8 hour) at Cycle 1 Day 15/AUC(0-8 hour) at Cycle 1 Day 1. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

Time frame:
Cycle 1 Days 1 and 15: 0-8 hours post-dose (Cycle length=21 days)
Reported as:
Geometric mean · ratio
DLT+Expansion Part, Rac (AUC0-8 Hour): Accumulation Ratio of AUC(0-8 Hour) for Lenvatinib
ratioDLT+Expansion Part, Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Japanese Participants: Lenvatinib 12 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg
DLT+Expansion Part, Rac (AUC0-8 Hour): Accumulation Ratio of AUC(0-8 Hour) for Lenvatinib1.07 ± 21.2—1.32 ± 44.81.83 ± 66.8
SecondaryDLT+Expansion Part, %PTF: Percent (%) Peak-trough Fluctuation for Lenvatinib

The PTF within complete dosing interval at steady state, calculated as PTF (%) = (\[Css,max - Css,min\]/Css,Av)\* 100. Where, Css,max is the maximum observed plasma concentration at steady state and Css,min is the minimum observed plasma concentration at steady state and Css,Av average steady state plasma concentration. As per PK planned analysis for lenvatinib and as per sponsor's practice, the lenvatinib PK data was collected, analyzed and summarized according to Japanese and non-Japanese population in this study.

Time frame:
Cycle 1 Day 15: 0-24 hours post-dose (Cycle length=21 days)
Reported as:
Geometric mean · percentage fluctuation
DLT+Expansion Part, %PTF: Percent (%) Peak-trough Fluctuation for Lenvatinib
percentage fluctuationDLT+Expansion Part, Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 8 mgDLT+Expansion Part, Japanese Participants: Lenvatinib 12 mgDLT+Expansion Part, Non-Japanese Participants: Lenvatinib 12 mg
DLT+Expansion Part, %PTF: Percent (%) Peak-trough Fluctuation for Lenvatinib——161 ± NA161 ± 34.0
SecondaryDLT+Expansion Part, Ctrough: Trough (Pre-dose) Serum Concentration for Pembrolizumab

Ctrough was defined as trough (pre-dose) serum concentration for pembrolizumab at steady state.

Time frame:
Cycles 1, 2, 4, 6, 8, 12, 16, 20, 24, 28, 32, 36: Pre-dose (each Cycle length=21 days)
Reported as:
Geometric mean · microgram per milliliter (mcg/mL)
DLT+Expansion Part, Ctrough: Trough (Pre-dose) Serum Concentration for Pembrolizumab
microgram per milliliter (mcg/mL)DLT+Expansion Part: Pembrolizumab 200 mg
Cycle 1: Pre-dose0.00 ± 0.00
Cycle 2: Pre-dose12.3 ± 40.7
Cycle 4: Pre-dose21.9 ± 56.6
Cycle 6: Pre-dose25.0 ± 64.7
Cycle 8: Pre-dose26.6 ± 86.1
Cycle 12: Pre-dose27.9 ± 57.7
Cycle 16: Pre-dose33.6 ± 39.3
Cycle 20: Pre-dose27.9 ± 50.1
Cycle 24: Pre-dose29.0 ± 69.9
Cycle 28: Pre-dose32.4 ± 49
Cycle 32: Pre-dose30.7 ± 34.3
Cycle 36: Pre-dose34.6 ± 40.2
SecondaryDLT+Expansion Part: Number of Participants Positive for Serum Anti-drug Antibodies (ADA) Status

ADA positive was defined as participants with at least one pre-treatment or post-dose sample positive in the confirmatory assay for antibodies against pembrolizumab. ADA was assessed using a validated electrochemiluminescence (ECL) immunoassay.

Time frame:
Cycles 1 and 6 Day 1: Pre-dose (each cycle length=21 days)
Reported as:
Count of participants · Participants
DLT+Expansion Part: Number of Participants Positive for Serum Anti-drug Antibodies (ADA) Status
ParticipantsHCC-1L: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg
Cycle 1 Day 1: Pre-dose3
Cycle 6 Day 1: Pre-dose0

Adverse events

Collected over From the date of administration of the first dose of the study drug up to 120 days after the last dose of study drug (up to 50.2 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DLT Part: Lenvatinib 12 mg or 8 mg + Pembrolizumab 200 mg5/6 (83.3%)4/6 (66.7%)6/6 (100%)
Expansion Part: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg67/98 (68.4%)73/98 (74.5%)97/98 (99%)
Most frequent serious events
Showing 10 of 104
Most frequent serious events
EventDLT Part: Lenvatinib 12 mg or 8 mg + Pembrolizumab 200 mgExpansion Part: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg
DiarrhoeaGastrointestinal disorders1/62/98
Inguinal herniaGastrointestinal disorders1/60/98
Aspartate aminotransferase increasedInvestigations1/63/98
Alanine aminotransferase increasedInvestigations1/61/98
Blood lactate dehydrogenase increasedInvestigations1/60/98
Subarachnoid haemorrhageNervous system disorders1/60/98
Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/60/98
Blood bilirubin increasedInvestigations0/69/98
Hepatic encephalopathyNervous system disorders0/66/98
PyrexiaGeneral disorders0/65/98
Most frequent other events
Showing 10 of 104
Most frequent other events
EventDLT Part: Lenvatinib 12 mg or 8 mg + Pembrolizumab 200 mgExpansion Part: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mg
Decreased appetiteMetabolism and nutrition disorders6/637/98
DiarrhoeaGastrointestinal disorders5/658/98
HypothyroidismEndocrine disorders4/631/98
Weight decreasedInvestigations4/633/98
HypertensionVascular disorders4/646/98
AnaemiaBlood and lymphatic system disorders3/628/98
NauseaGastrointestinal disorders3/620/98
Oedema peripheralGeneral disorders3/620/98
Neutrophil count decreasedInvestigations3/68/98
Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/60/98

Baseline characteristics

The efficacy analysis set included all participants who had received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)DLT Part: Lenvatinib 12 mg or 8 mg + Pembrolizumab 200 mgExpansion Part: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mgTotal
Mean65.2 ± 10.1166.2 ± 8.1666.1 ± 8.23
Sex: Female, Male
Sex: Female, Male(Participants)DLT Part: Lenvatinib 12 mg or 8 mg + Pembrolizumab 200 mgExpansion Part: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mgTotal
Female11920
Male57984
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)DLT Part: Lenvatinib 12 mg or 8 mg + Pembrolizumab 200 mgExpansion Part: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mgTotal
Hispanic or Latino033
Not Hispanic or Latino67884
Unknown or Not Reported01717
Race (NIH/OMB)
Race (NIH/OMB)(Participants)DLT Part: Lenvatinib 12 mg or 8 mg + Pembrolizumab 200 mgExpansion Part: Lenvatinib 12 mg or 8 mg+ Pembrolizumab 200 mgTotal
American Indian or Alaska Native000
Asian62632
Native Hawaiian or Other Pacific Islander000
Black or African American022
White05151
More than one race000
Unknown or Not Reported01919
08

Study locations

26 sites
  • California Pacific Medical Center (CPMC)
    San Francisco, California 94115, United States
  • Ronald Reagan UCLA Medical Center
    Santa Monica, California 90095, United States
  • Mercy Medical Center
    Baltimore, Maryland 21202, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Icahn School of Medicine Mount Sinai
    New York, New York 10029, United States
  • BRCR Global Texas
    Edinburg, Texas 78539, United States
  • Hôpital Haut-Levêque Centre médico-chirurgical Magellan
    Pessac, Bordeaux 33604, France
  • Centre Eugène Marquis de Rennes
    Rennes, Brittany 35042, France
  • CHU Toulouse
    Toulouse, Occitanie 31059, France
  • Hôpital Timone
    Marseille, Provence-Alpes-Côte d'Azur 13005, France
  • IRCCS Istituto Clinico Humanitas
    Milan, Lombardy 20089, Italy
  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
    Bologna, Province Of Bologna 15-40138, Italy
  • Eisai Trial Site 2
    Kashiwa, Chiba, Japan
  • Eisai Trial Site 4
    Kawasaki, Kanagawa, Japan
  • Eisai Trial Site 3
    Sayama, Osaka, Japan
  • Eisai Trial Site 1
    Chuo-ku, Tokyo, Japan
  • Republican Clinical Oncology Dispensary
    Ufa, Bashkortostan, Russian Federation
  • St. Petersburg City Clinical Oncology Dispansery
    Saint Petersburg, Leningrad Oblast, Russian Federation
  • S.I. Russian Oncological Research Center n.a. N. N. Blokhin RAMS
    Moscow, Moscow Oblast, Russian Federation
  • Altay Regional Oncology Dispensary
    Barnaul, Russian Federation
  • Hospital Universitario Marqués de Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital General Universitario Gregorio Marañón
    Madrid, Community Of Madrid 28007, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, Community Of Madrid 28041, Spain
  • Hospital Infanta Cristina de Badajoz
    Badajoz, Province Of Badajoz 06080, Spain
  • Hospital Universitario de Salamanca
    Salamanca, Province Of Salamanca 37007, Spain
  • Royal Free Hospital
    London, Greater London NW3 2QG, United Kingdom
09

References and documents

Publications

  • Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27. PubMed 32716739 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2017 to primary completion in Oct 2019, 32 months.

Results were first posted in Dec 2020, 1 year 2 months after primary completion.

Of 103 industry-sponsored phase 1 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's 32 months is below that.

Counting every sponsor, half of 248 studies reached it within 49 months; a quarter within 32 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2016
First posted
Dec 30, 2016
StartActual
Feb 13, 2017
Primary completionActual
Oct 31, 2019
CompletionActual
Nov 22, 2022
Results first posted
Dec 31, 2020
Last update
Dec 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03006926
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Dec 30, 2016
Start date
Feb 13, 2017
Primary completion
Oct 31, 2019
Completion
Nov 22, 2022
Results posted
Dec 31, 2020
Last update
Dec 13, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenvatinib · Pembrolizumab

Start the discussion